Therefore, Oxygen-sensing prolyl hydroxylase (PHD) is responsible for proteasomal degradation, and factor inhibiting hypoxia (FIH) for transcription activity could be a therapeutic target for hypoxia in lung cancer. This evidence concerns the gene PDC and lung carcinoma.